Passage Bio PASG Stock
Passage Bio Price Chart
Passage Bio PASG Financial and Trading Overview
| Passage Bio stock price | 5.97 USD |
| Previous Close | 5.77 USD |
| Open | 5.72 USD |
| Bid | 4.21 USD x 200 |
| Ask | 7.43 USD x 200 |
| Day's Range | 5.58 - 5.93 USD |
| 52 Week Range | 3.94 - 20 USD |
| Volume | 18.42K USD |
| Avg. Volume | 79.6K USD |
| Market Cap | 18.77M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.84 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.4 USD |
PASG Valuation Measures
| Enterprise Value | -8815312 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.76171875 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.9927032 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.239 |
Trading Information
Passage Bio Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -41.38% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 20 USD |
| 52 Week Low | 3.94 USD |
| 50-Day Moving Average | 6.68 USD |
| 200-Day Moving Average | 8.52 USD |
PASG Share Statistics
| Avg. Volume (3 month) | 79.6K USD |
| Avg. Daily Volume (10-Days) | 32.24K USD |
| Shares Outstanding | 3.21M |
| Float | 2.89M |
| Short Ratio | 1.12 |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 58.32% |
| Shares Short | 162.63K |
| Short % of Float | 6.32% |
| Short % of Shares Outstanding | 5.07% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -38.35% |
| Return on Equity (ttm) | -128.89% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -36920000 USD |
| Net Income Avi to Common (ttm) | -37676000 USD |
| Diluted EPS (ttm) | -11.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 33.34M USD |
| Total Cash Per Share (mrq) | 10.39 USD |
| Total Debt (mrq) | 5.76M USD |
| Total Debt/Equity (mrq) | 48.97 USD |
| Current Ratio (mrq) | 1.728 |
| Book Value Per Share (mrq) | 5.893 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -30649000 USD |
| Levered Free Cash Flow (ttm) | -13150000 USD |
Profile of Passage Bio
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | One Commerce Square |
| ZIP | 19103 |
| Phone | 267 866 0311 |
| Website | https://www.passagebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 24 |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Q&A For Passage Bio Stock
What is a current PASG stock price?
Passage Bio PASG stock price today per share is 5.97 USD.
How to purchase Passage Bio stock?
You can buy PASG shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Passage Bio?
The stock symbol or ticker of Passage Bio is PASG.
Which industry does the Passage Bio company belong to?
The Passage Bio industry is Biotechnology.
How many shares does Passage Bio have in circulation?
The max supply of Passage Bio shares is 3.21M.
What is Passage Bio Price to Earnings Ratio (PE Ratio)?
Passage Bio PE Ratio is now.
What was Passage Bio earnings per share over the trailing 12 months (TTM)?
Passage Bio EPS is -11.84 USD over the trailing 12 months.
Which sector does the Passage Bio company belong to?
The Passage Bio sector is Healthcare.
Passage Bio PASG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}